COVID Vaccine Developer/Manufacturer Announcements [relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

Milestones :: Perspectives :: Research

 

COVID Vaccine Developer/Manufacturer Announcements [relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

 

AstraZeneca
Press Releases – No new digest announcements identified

BioCubaFarma – Cuba
Últimas Noticias
La apuesta de Cuba por el desarrollo de vacunas propias contra la Covid19 tiene una experiencia de más de 30 años.
24/06/2021 23:27:18

[google translate: Cuba’s commitment to the development of its own vaccines against Covid19 has an experience of more than 30 years. 06/24/2021 11:27:18 PM]

 

CanSinoBIO
News
CanSinoBIO Announces Approval for Its Group A and Group C Meningococcal Conjugate Vaccine in China
2021-06-23

Clover Biopharmaceuticals – China
News – No new digest announcements identified

 

Curevac [Bayer Ag – Germany]
News Home – No new digest announcements identified

 

Gamaleya National Center
Latest News and Events – No new digest announcements identified [See Russia/RFID below]

IMBCAMS, China
Home – No new digest announcements identified

 

Janssen/JNJ
Press Releases – No new digest announcements identified

 

Moderna
Press Releases
June 22, 2021
European Commission Purchases Additional 150 Million Doses of Moderna’s COVID-19 Vaccine for Delivery in 2022

 

Novavax
Press Releases
Novavax Statement on Completion of the National Research Council of Canada Biologics Manufacturing Centre
Jun 22, 2021
The Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry announced today that construction of the new Biologics Manufacturing Centre (BMC) at the National Research Council of Canada’s (NRC)’s Royalmount location in Montréal, Québec has been completed.
The partnership will enable the first manufacturing capabilities in Canada for a COVID-19 vaccine once the facility and NVX-CoV2373, Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine candidate, receive the required Health Canada approvals. Novavax and the NRC are working closely together on technology transfer to establish the step-by-step process of producing NVX-CoV2373 at the BMC…

 

Pfizer
Recent Press Releases – No new digest announcements identified

 

Sanofi Pasteur
Press Releases
June 22 2021 Press releases
Sanofi and Translate Bio initiate Phase 1 clinical trial of mRNA influenza vaccine

 

Serum Institute of India
NEWS & ANNOUNCEMENTS – No corporate announcements identified
[Last media release April 21, 2021]

 

Sinopharm/WIBPBIBP
News – Website not responding at inquiry

 

Sinovac
Press Releases – No new digest announcements identified

 

Vector State Research Centre of Viralogy and Biotechnology
Home – No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
[No website identified]

 

::::::

GSK
Press releases for media
New GSK to deliver step-change in growth and performance over next ten years driven by high-quality Vaccines and Specialty Medicines portfolio and late-stage pipeline
23 June 2021
Maximising Vaccines and Specialty Medicines
New GSK will prioritise R&D and commercial investment in Vaccines and Specialty Medicines, which are expected to grow to around three-quarters of company sales by 2026. As part of its 2021-26 outlook, Vaccines is expected to grow sales at a high single-digit % CAGR and Specialty Medicines at a double-digit % CAGR.
The company is focused across four core therapeutic areas (TAs): Infectious Diseases, HIV, Oncology and Immunology/Respiratory. In addition, New GSK will remain open to opportunities outside these core TAs where there are scale opportunities rooted in immune science and genetic validation.
Capturing the increasing opportunities now seen across the prevention and treatment of disease offers significant scientific and commercial opportunities for New GSK. At the heart of this is the company’s R&D focus on the science of the immune system, human genetics and advanced technologies; and its world-leading capabilities in vaccine and pharmaceutical development.
The company currently has a pipeline of 20 vaccines and 42 medicines – many of which are potential best or first in class opportunities…

 

SK Biosciences
Press releases
SK bioscience to Sign MOU with Andong and North Gyeongsang Province for Expansion of Factories and Sites
SK invested about 150 billion won in the expansion of existing vaccine manufacturing plants used for mRNA…
2021. 06. 21